new glp 1 agonist for weight loss Hitting the Triple G Spot: The Triple G GLP-1 Agonists for Weight Loss:

Ozempic is given as a subcutaneous injection once a week, under the skin of the stomach, thigh or upper arm

P = 0.04), a main contributor to the reduction of 3-MACE composite endpoint (253)

Furthermore, tirzepatide has shown excellent cardiovascular safety

Interestingly, the mean values remain relatively normal in most T2DM groups (3133), suggesting that the impaired incretin releases are not a typical prerequisite for the development of T2DM

Girish PJ, Abdelmalak BB, Weigal WA, et al

A recent meta-analysis involving 32,884 patients from 19 randomized controlled trials further confirmed a 23% reduction in all-cause mortality associated with GLP-1RAs use (OR = 0.77) (Rivera et al., 2024)